GCG and Insulin resistance: Furthermore, several recent trials have shown that interventions targeting the improvement of insulin resistance, such as glucagon-like peptide-1 analogues (GLP-1) [41], sodium–glucose cotransporter 2 inhibitors (SGLT-2i) [42], and thiazolidinediones (TZDs) [43], have the potential to further mitigate the risk of adverse cardiovascular events in both diabetic and non-diabetic individuals.